Protagonist details rusfertide Ph3 enrollment, JNJ-2113 milestones, cash runway through Q1 2026

Protagonist Therapeutics, Inc

Rusfertide VERIFY Ph3 enrollment expected to complete 1Q24; NDA filing planned for Q4 2024.
JNJ-2113 ICONIC Ph3 program ongoing; ANTHEM UC Ph2b expected completion ~May 2025.
Oral IL-17 peptide antagonist development candidate on track for 2024.
Cash runway forecast through Q1 2026; $215M potential milestones from Janssen not included.
$172.5M in upfront and development milestones achieved, including $60M in Q4 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.